GSK plc Announces Third Tranche of Share Buyback Program
Ticker: GLAXF · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, capital-return, disclosure
TL;DR
GSK launching 3rd share buyback tranche, returning more cash to investors.
AI Summary
GSK plc announced on September 30, 2025, the third tranche of its share buyback program, which commenced on February 24, 2025, with an initial total of £2 billion. This filing is a report of foreign private issuer.
Why It Matters
This indicates GSK is returning capital to shareholders, potentially signaling confidence in its financial position and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a share buyback program, which is a common corporate action.
Key Numbers
- £2 billion — Share Buyback Program Value (Total amount allocated for share repurchases.)
Key Players & Entities
- GSK plc (company) — Registrant
- £2 billion (dollar_amount) — Total value of share buyback program
- 30 September 2025 (date) — Date of report issuance
- 24 February 2025 (date) — Date of buyback program commencement
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is to report the third tranche of GSK plc's share buyback program.
When did GSK plc announce the commencement of its share buyback program?
GSK plc announced the commencement of its share buyback program on 24 February 2025.
What is the total value of the share buyback program announced?
The total value of the share buyback program is £2 billion.
What is the filing date of this report?
This report was issued on 30 September 2025.
What is the principal executive office address of GSK plc?
The principal executive office address of GSK plc is 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 855 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2025-09-30 07:56:14
Filing Documents
- a3115b.htm (6-K) — 30KB
- 0001654954-25-011211.txt ( ) — 31KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: September 30, 2025         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc